Menu Search
Equities

AB Science SA

AB:PAR

AB Science SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)2.10
  • Today's Change-0.11 / -4.98%
  • Shares traded188.93k
  • 1 Year change-51.67%
  • Beta0.7486
Data delayed at least 15 minutes, as of May 17 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year AB Science SA had revenues fall -40.39% from 1.61m to 958.00k, though the company grew net income from a loss of 14.46m to a smaller loss of 13.62m.
Gross margin88.16%
Net profit margin-2,173.10%
Operating margin-1,959.46%
Return on assets-61.64%
Return on equity--
Return on investment-237.22%
More ▼

Cash flow in EURView more

In 2022, cash reserves at AB Science SA fell by 1.45m. Cash Flow from Financing totalled 16.39m or 1,710.96% of revenues. In addition the company used 17.47m for operations while cash used for investing totalled 360.00k.
Cash flow per share-0.1921
Price/Cash flow per share--
Book value per share-0.3879
Tangible book value per share-0.42
More ▼

Balance sheet in EURView more

AB Science SA appears to have a weak balance sheet, highlighted by its negative owner's equity.
Current ratio1.43
Quick ratio1.41
Total debt/total equity--
Total debt/total capital135.44
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.